Results of kidney transplantation at Necker Hospital

Area of Science:

• Immunosuppression in transplantation
• Nephrology
• Transplant immunology

Background:

• Kidney transplant rejection remains a significant challenge.
• Various immunosuppressive agents are used to prevent rejection.
• Optimizing immunosuppressive therapy is crucial for graft survival and function.

Purpose of the Study:

• To compare the efficacy of different immunosuppressive therapies in kidney transplant recipients.
• To evaluate the impact of therapy duration and specific agents on rejection rates and graft function.
• To assess the safety and effectiveness of combination therapies.

Main Methods:

• Retrospective analysis of patient data comparing different immunosuppressive protocols.
• Evaluation of therapies including antithymocyte globulin (ATG) and Orthoclone OKT3 (OKT3).
• Comparison of short-term versus long-term ATG therapy and combination regimens with Cyclosporine (CsA).

Main Results:

• Long-term ATG therapy showed only a marginal improvement over shorter courses.
• Both OKT3 and ATG were effective in preventing rejection, with OKT3 demonstrating slightly superior efficacy.
• Prophylactic OKT3 therapy resulted in enhanced graft function compared to other regimens.

Conclusions:

• OKT3 appears to be a slightly more effective agent than ATG for preventing transplant rejection.
• Prophylactic use of OKT3 can improve early graft function.
• A 21-day course of OKT3 followed by CsA may be detrimental compared to ATG + CsA combination therapy.